KEYNOTE-671: Randomized, double-blind, phase 3 study of pembrolizumab or placebo plus platinum-based chemotherapy followed by resection and pembrolizumab or placebo for early stage NSCLC.

被引：0
|
作者：
Wakelee, Heather A.
Liberman, Moishe
Kato, Terufumi
Tsuboi, Masahiro
Lee, Se-Hoon
He, Jie
Gao, Shugeng
Chen, Ke-Neng
Dooms, Christophe Alfons
Majem, Margarita
Eigendorff, Ekkehard
Martinengo, Gaston Lucas
Bylicki, Olivier
Rodriguez-Abreu, Delvys
Chaft, Jamie E.
Novello, Silvia
Yang, Jing
Keller, Steven M.
Samkari, Ayman
Spicer, Jonathan
机构：
[1] Stanford Univ, Stanford Canc Inst, Div Oncol, Dept Med, Stanford, CA USA
[2] Ctr Hosp Univ Montreal, Montreal, PQ, Canada
[3] Kanagawa Canc Ctr, Yokohama, Kanagawa, Japan
[4] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan
[5] Sungkyunkwan Univ, Div Hematol Oncol, Dept Internal Med, Samsung Med Ctr,Sch Med, Seoul, South Korea
[6] Chinese Acad Med Sci & Peking, Natl Canc Ctr, Natl Clin Res Ctr Canc, Canc Hosp, Beijing, Peoples R China
[7] Chinese Acad Med Sci & Pek, Dept Thorac Surg, Natl Clin Res Ctr Canc, Canc Hosp,Natl Canc Ctr, Beijing, Peoples R China
[8] Beijing Canc Hosp, Beijing, Peoples R China
[9] Univ Hosp Leuven, Leuven, Belgium
[10] Hosp Santa Creu & Sant Pau, Dept Med Oncol, Barcelona, Spain
[11] Zentralklin Bad Berka GmbH, Bad Berka, Germany
[12] Sanatorio Parque, Santa Fe, Argentina
[13] HIA SAINTE ANNE, Toulon, France
[14] Complejo Hosp Univ Insular Materno Infantil, Las Palmas Gran Canaria, Spain
[15] Mem Sloan Kettering Canc Ctr, New York, NY USA
[16] Univ Turin, AOU San Luigi Orbassano, Turin, Italy
[17] Merck & Co Inc, Rahway, NJ USA
[18] Merck & Co Inc, Kenilworth, NJ USA
[19] McGill Univ, Ctr Hlth, Montreal, PQ, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 17期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA100
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Phase III study of neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for early-stage triple-negative breast cancer (TNBC): KEYNOTE-522 Korean subgroup analysis
    Park, Y. H.
    Im, S-A.
    Ahn, J-H.
    Kim, M. H.
    Cortes, J.
    Dent, R. A.
    Pusztai, L.
    McArthur, H. L.
    Kummel, S.
    Denkert, C.
    O'Shaughnessy, J.
    Mouret-Reynier, M-A.
    Ferreira, M. I. R.
    Cortes, M. Gion
    Boileau, J-F.
    Hui, R.
    Zhu, Y.
    Pan, W.
    Karantza, V. V.
    Schmid, P.
    ANNALS OF ONCOLOGY, 2023, 34 : S1467 - S1468
  • [22] KEYNOTE-811 pembrolizumab plus trastuzumab and chemotherapy for HER2+metastatic gastric or gastroesophageal junction cancer: a double-blind, randomized, placebo -controlled phase 3 study
    Chung, H.
    Bang, Y.
    Fuchs, C.
    Qin, S.
    Satoh, T.
    Shitara, K.
    Tabernero, J.
    Van Cutsem, E.
    Cao, Z.
    Chen, X.
    Kang, S.
    Shih, C.
    Janjigian, Y.
    ANNALS OF ONCOLOGY, 2019, 30 : 25 - 25
  • [23] Phase 3 study of neoadjuvant pembrolizumab or placebo plus chemotherapy, followed by adjuvant pembrolizumab or placebo plus endocrine therapy for early-stage high-risk ER+/ HER2-breast cancer: KEYNOTE-756
    Cardoso, Fatima
    O'Shaughnessy, Joyce
    McArthur, Heather
    Schmid, Peter
    Cortes, Javier
    Harbeck, Nadia
    Telli, Melinda
    Cescon, David
    Fasching, Peter A.
    Shao, Zhimin
    Loirat, Delphine
    Park, Yeon Hee
    Fernandez, Manuel Gonzalez
    Rubovszky, Gabor
    Im, Seock-Ah
    Hui, Rina
    Takano, Toshimi
    Andre, Fabrice
    Yasojima, Hiroyuki
    Liu, Zhenzhen
    Ding, Yu
    Jia, Liyi
    Karantza, Vassiliki
    Tryfonidis, Konstantinos
    Bardia, Aditya
    CANCER RESEARCH, 2024, 84 (09)
  • [24] ECHO-306/KEYNOTE-715: A phase 3 study of first-line epacadostat plus pembrolizumab with or without platinum-based chemotherapy vs pembrolizumab plus platinum-based chemotherapy plus placebo for metastatic non-small cell lung cancer (mNSCLC)
    Hui, Rina
    Munteanu, Mihaela
    Zhao, Yufan
    Luo, Yiwen
    Samkari, Ayman
    Garassino, Marina Chiara
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [25] A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED PHASE III STUDY EVALUATING PERIOPERATIVE TORIPALIMAB COMBINED WITH PLATINUM-BASED DOUBLET CHEMOTHERAPY IN RESECTABLE STAGE III NSCLC
    Wang, Wenxiang
    Wu, Lin
    Zhang, Wei
    Lu, Shun
    Fang, Haohui
    Yu, Guohua
    Zhou, Ming
    Xing, Wenqun
    Chen, Qixun
    Li, Xingya
    Yang, Nong
    Ye, Minhua
    Fang, Wentao
    Huang, Yunchao
    Liu, Jichun
    Tan, Lijie
    Hang, Xiaosheng
    Zhang, Wengang
    Zhang, Liwei
    Chen, Jun
    Zhang, Xun
    Zhang, Yu
    Jiang, Jie
    Zhong, Aihong
    Li, Shanqing
    Liu, Yunpeng
    Wu, Guowu
    Kang, Xiaoyan
    Tian, Ying
    Xu, Tao
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A223 - A224
  • [26] Neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for early-stage triple-negative breast cancer: Updated event-free survival results from the phase 3 KEYNOTE-522 study
    Schmid, Peter
    Cortes, Javier
    Dent, Rebecca
    Pusztai, Lajos
    McArthur, Heather
    Kuemmel, Sherko
    Denkert, Carsten
    Park, Yeon Hee
    Hui, Rina
    Harbeck, Nadia
    Takahashi, Masato
    Foukakis, Theodoros
    Mouret-Reynier, Marie-Ange
    Ferreira, Marta
    Im, Seock-Ah
    Cardoso, Fatima
    Ding, Yu
    Pan, Wilbur
    Tryfonidis, Konstantinos
    O'Shaughnessy, Joyce
    CANCER RESEARCH, 2024, 84 (09)
  • [27] Neoadjuvant pembrolizumab plus chemotherapy versus placebo plus chemotherapy, followed by adjuvant pembrolizumab versus placebo for early-stage TNBC: Event-free survival sensitivity and subgroup analyses from KEYNOTE-522
    Schmid, Peter
    Cortes, Javier
    Dent, Rebecca
    Pusztai, Lajos
    McArthur, Heather
    Kuemmel, Sherko
    Bergh, Jonas
    Denkert, Carsten
    Park, Yeon Hee
    Hui, Rina
    Harbeck, Nadia
    Takahashi, Masato
    Untch, Michael
    Fasching, Peter A.
    Cardoso, Fatima
    Andersen, Jay
    Patt, Debra
    Danso, Michael
    Ferreira, Marta
    Mouret-Reynier, Marie-Ange
    Im, Seock-Ah
    Ahn, Jin Hee
    Gion, Maria
    Baron-Hay, Sally
    Boileau, Jean-Francois
    Zhu, Yalin
    Pan, Wilbur
    Tryfonidis, Konstantinos
    Karantza, Vassiliki
    O'Shaughnessy, Joyce
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022, 18 : 117 - 118
  • [28] KEYNOTE-826: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF PEMBROLIZUMAB PLUS CHEMOTHERAPY FOR FIRST-LINE TREATMENT OF PERSISTENT, RECURRENT, OR METASTATIC CERVICAL CANCER
    Tewari, K.
    Caceres, M. V.
    Alexandre, J.
    Monk, B.
    Fehm, T.
    Colombo, N.
    Hasegawa, K.
    Dubot, C.
    Li, J. J.
    Stein, K.
    Keefe, S.
    Shapira-Frommer, R.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2019, 29 : A162 - A162
  • [29] Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study
    Rudin, Charles M.
    Awad, Mark M.
    Navarro, Alejandro
    Gottfried, Maya
    Peters, Solange
    Csoszi, Tibor
    Cheema, Parneet K.
    Rodriguez-Abreu, Delvys
    Wollner, Mirjana
    Yang, James Chih-Hsin
    Mazieres, Julien
    Orlandi, Francisco J.
    Luft, Alexander
    Gumus, Mahmut
    Kato, Terufumi
    Kalemkerian, Gregory P.
    Luo, Yiwen
    Ebiana, Victoria
    Pietanza, M. Catherine
    Kim, Hye Ryun
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (21) : 2369 - +
  • [30] Safety evaluation from the KEYNOTE-522 study of neoadjuvant pembrolizumab (or placebo) plus chemotherapy followed by adjuvant pembrolizumab (or placebo) in patients with early triple-negative breast cancer (TNBC)
    Cortes, Javier
    Dent, Rebecca
    Pusztai, Lajos
    McArthur, Heather
    Kuemmel, Sherko
    Denkert, Carsten
    Park, Yeon Hee
    Hui, Rina
    Takahashi, Masato
    Barrios, Carlos
    Zhu, Yalin
    Zhang, Xiaoli
    Pan, Wilbur
    Karantza, Vassiliki
    O'Shaughnessy, Joyce
    Schmid, Peter
    CANCER RESEARCH, 2024, 84 (09)
12345